These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 27255997)

  • 1. MUS81 is associated with cell proliferation and cisplatin sensitivity in serous ovarian cancer.
    Xie S; Zheng H; Wen X; Sun J; Wang Y; Gao X; Guo L; Lu R
    Biochem Biophys Res Commun; 2016 Aug; 476(4):493-500. PubMed ID: 27255997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of MUS81 improves the chemical sensitivity of olaparib by regulating MCM2 in epithelial ovarian cancer.
    Zhong A; Zhang H; Xie S; Deng M; Zheng H; Wang Y; Chen M; Lu R; Guo L
    Oncol Rep; 2018 Apr; 39(4):1747-1756. PubMed ID: 29393493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
    Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
    Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian serous carcinomas acquire cisplatin resistance and increased invasion through downregulation of the high-temperature-required protein A2 (HtrA2), following repeated treatment with cisplatin.
    Soyama H; Miyamoto M; Takano M; Aoyama T; Matsuura H; Sakamoto T; Takasaki K; Kuwahara M; Kato K; Yoshikawa T; Iwahashi H; Tsuda H; Furuya K
    Med Oncol; 2017 Nov; 34(12):201. PubMed ID: 29168038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Influence of mifepristone on DNA repair genes and cisplatin sensitivity in human ovarian cancer drug-resistance cells].
    Liu GY; Qu QX; Mi RR; Qi J
    Zhonghua Fu Chan Ke Za Zhi; 2008 Feb; 43(2):132-5. PubMed ID: 18683754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression.
    Li QQ; Yunmbam MK; Zhong X; Yu JJ; Mimnaugh EG; Neckers L; Reed E
    Cell Mol Biol (Noisy-le-grand); 2001; 47 Online Pub():OL61-72. PubMed ID: 11936875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer].
    Liu GY; Qu QX; Mi RR; Qi J
    Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):184-7. PubMed ID: 18756932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma.
    Jagadish N; Fatima R; Sharma A; Devi S; Suri V; Kumar V; Suri A
    Tumour Biol; 2018 May; 40(5):1010428318773652. PubMed ID: 29745297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
    Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
    Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knockdown of BRCA2 enhances cisplatin and cisplatin-induced autophagy in ovarian cancer cells.
    Wan B; Dai L; Wang L; Zhang Y; Huang H; Qian G; Yu T
    Endocr Relat Cancer; 2018 Jan; 25(1):69-82. PubMed ID: 29066501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
    Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
    Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line.
    Du P; Zhang X; Liu H; Chen L
    DNA Cell Biol; 2015 Jul; 34(7):497-502. PubMed ID: 25941922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair.
    Kudo K; Gavin E; Das S; Amable L; Shevde LA; Reed E
    Oncogene; 2012 Nov; 31(44):4718-24. PubMed ID: 22266871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CST2 promotes cell proliferation and regulates cell cycle by activating Wnt-β-catenin signalling pathway in serous ovarian cancer.
    Wang X; Zhao S; Guo Y; Wang C; Han S; Wang X
    J Obstet Gynaecol; 2024 Dec; 44(1):2363515. PubMed ID: 38864487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impacts of ERCC1 gene exon VIII alternative splicing on cisplatin-resistance in ovarian cancer cells.
    Sun Y; Li T; Ma K; Tian Z; Zhu Y; Chen F; Hu G
    Cancer Invest; 2009 Nov; 27(9):891-7. PubMed ID: 19832035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer.
    Reed E; Yu JJ; Davies A; Gannon J; Armentrout SL
    Clin Cancer Res; 2003 Nov; 9(14):5299-305. PubMed ID: 14614013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
    Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
    Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma.
    Sung PL; Jan YH; Lin SC; Huang CC; Lin H; Wen KC; Chao KC; Lai CR; Wang PH; Chuang CM; Wu HH; Twu NF; Yen MS; Hsiao M; Huang CY
    Oncotarget; 2016 Jan; 7(4):4036-47. PubMed ID: 26716408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Enhanced cisplatin cytotoxicity by RNA interfering the excision repair cross-complementing 1 gene in ovarian cancer cell lines].
    Liu GY; Qu QX; Mi RR; Qi J
    Zhonghua Fu Chan Ke Za Zhi; 2006 May; 41(5):339-42. PubMed ID: 16762192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Inhibition of Topo II alpha gene expression and reversing of drug resistance in multi-drug resistant epithelial ovarian cancer cells induced by RNA interference in vitro].
    He J; Li L; Tang BJ; Zhang W; Li DR; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2009 Sep; 44(9):686-90. PubMed ID: 20079182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.